Efficacy News and Research

RSS
Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD

Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD

BIDPO implements Ingenix technology to measure clinical, operational performance

BIDPO implements Ingenix technology to measure clinical, operational performance

Pyrethroid insecticides linked to delayed mental development in children

Pyrethroid insecticides linked to delayed mental development in children

Sorin's 2010 consolidated revenues increase 4.9% to € 745.8 million

Sorin's 2010 consolidated revenues increase 4.9% to € 745.8 million

RF-induced heat therapy could help treat common parasitic skin infection

RF-induced heat therapy could help treat common parasitic skin infection

Times of India examines dengue vaccine trials

Times of India examines dengue vaccine trials

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

Vical 2010 net loss increases to $30.4 million

Vical 2010 net loss increases to $30.4 million

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Indiana University creates Institute for Personalized Medicine

Indiana University creates Institute for Personalized Medicine

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

WIN Consortium proposes unique alliance to fight cancer

WIN Consortium proposes unique alliance to fight cancer

Liquidia to explore PRINT particle technology with PATH Malaria Vaccine Initiative

Liquidia to explore PRINT particle technology with PATH Malaria Vaccine Initiative

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

New study: Fetal surgery for spina bifida greatly improves child's mobility

New study: Fetal surgery for spina bifida greatly improves child's mobility

Evotec signs definitive agreement to acquire all shares in Kinaxo

Evotec signs definitive agreement to acquire all shares in Kinaxo

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.